Bristol Myers gets positive opinion from CHMP for Opdivo
The therapy is intended for adults and adolescents aged 12 years and above. This recommendation will be forwarded to the European Commission (EC), which will make a final
The therapy is intended for adults and adolescents aged 12 years and above. This recommendation will be forwarded to the European Commission (EC), which will make a final
Earlier known as AV7909, CYFENDUS vaccine’s efficacy for post-exposure prophylaxis is only based on studies in animal models of inhalational anthrax. Emergent senior vice president, science and development
ORLADEYO (berotralstat) is claimed to be the first and only oral treatment intended particularly to prevent attacks of hereditary angioedema (HAE) in adult and paediatric patients aged 12 years
The US products are FLAREX, NATACYN, TOBRADEX, VERKAZIA, ZERVIATE, FRESHKOTE, while the Canadian products are VERKAZIA, Cationorm PLUS. FLAREX (fluorometholone acetate ophthalmic suspension) is indicated for treating steroid-responsive
Under the collaboration, the companies will leverage Eleven’s DELiveri platform that uses DNA-encoded libraries (DELs), for identifying new molecules that promote precise nucleic acid delivery for treating cardiometabolic
This therapy is intended for use in patients with severe renal impairment including those on dialysis. The latest announcement comes after the decision from European Commission to extend
The FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor Brenzavvy is available as 20 mg tablet and is recommended once daily in the morning with or without food. It
In April this year, Astellas Pharma’s subsidiary agreed to buy 100% of the outstanding shares of Iveric Bio for $40 per share in cash for a total equity value of about
The provisional approval comes with a duration of two years. It is based on the data from Phase II studies that enrolled highly sensitised patients who received imlifidase
The label update reinforces the safety and effectiveness data of Leqvio generated by the VictORION clinical trial programme, claimed the company. Leqvio was initially approved by the FDA